The drug is in preclinical stages and aims to target cardiometabolic benefits, including weight reduction, according to a Dec. 18 news release from Merck. Under the agreement, Merck will have exclusive rights to develop, manufacture and commercialize the drug worldwide.
Hansoh Pharma will receive an upfront payment of $112 million, with the potential for an additional $1.9 billion in milestone payments tied to the drug’s development, regulatory approval and commercialization.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
